228 related articles for article (PubMed ID: 21030067)
1. Overexpression of transforming growth factor β1 in malignant prostate cells is partly caused by a runaway of TGF-β1 auto-induction mediated through a defective recruitment of protein phosphatase 2A by TGF-β type I receptor.
Yu N; Kozlowski JM; Park II; Chen L; Zhang Q; Xu D; Doll JA; Crawford SE; Brendler CB; Lee C
Urology; 2010 Dec; 76(6):1519.e8-13. PubMed ID: 21030067
[TBL] [Abstract][Full Text] [Related]
2. D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.
Vásquez R; Farías M; Vega JL; Martin RS; Vecchiola A; Casanello P; Sobrevia L
J Cell Physiol; 2007 Sep; 212(3):626-32. PubMed ID: 17427197
[TBL] [Abstract][Full Text] [Related]
3. Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.
Romero D; Terzic A; Conley BA; Craft CS; Jovanovic B; Bergan RC; Vary CP
Carcinogenesis; 2010 Mar; 31(3):359-66. PubMed ID: 19736306
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer.
Guo Y; Jacobs SC; Kyprianou N
Int J Cancer; 1997 May; 71(4):573-9. PubMed ID: 9178810
[TBL] [Abstract][Full Text] [Related]
5. Transforming Growth Factor β1-induced Apoptosis in Podocytes via the Extracellular Signal-regulated Kinase-Mammalian Target of Rapamycin Complex 1-NADPH Oxidase 4 Axis.
Das R; Xu S; Nguyen TT; Quan X; Choi SK; Kim SJ; Lee EY; Cha SK; Park KS
J Biol Chem; 2015 Dec; 290(52):30830-42. PubMed ID: 26565025
[TBL] [Abstract][Full Text] [Related]
6. Expression of transforming growth factor-beta receptor type I and type II in rat ventral prostate and Dunning R3327 PAP adenocarcinoma in response to castration and oestrogen treatment.
Wikström P; Bergh A; Damber JE
Urol Res; 1997; 25(2):103-11. PubMed ID: 9144876
[TBL] [Abstract][Full Text] [Related]
7. Alterations of transforming growth factor beta1 (TGF-beta1) and TGFbeta receptor expressions with progression in Dunning rat prostatic adenocarcinoma sublines.
Wikström P; Lindh G; Bergh A; Damber JE
Urol Res; 1999 Jun; 27(3):185-93. PubMed ID: 10422820
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta (TGF-beta1) activates TAK1 via TAB1-mediated autophosphorylation, independent of TGF-beta receptor kinase activity in mesangial cells.
Kim SI; Kwak JH; Na HJ; Kim JK; Ding Y; Choi ME
J Biol Chem; 2009 Aug; 284(33):22285-22296. PubMed ID: 19556242
[TBL] [Abstract][Full Text] [Related]
9. Activation of extracellular signal-regulated kinase by TGF-beta1 via TbetaRII and Smad7 dependent mechanisms in human bronchial epithelial BEP2D cells.
Huo YY; Hu YC; He XR; Wang Y; Song BQ; Zhou PK; Zhu MX; Li G; Wu DC
Cell Biol Toxicol; 2007 Mar; 23(2):113-28. PubMed ID: 17096210
[TBL] [Abstract][Full Text] [Related]
10. Novel permissive role of epidermal growth factor in transforming growth factor beta (TGF-beta) signaling and growth suppression. Mediation by stabilization of TGF-beta receptor type II.
Song K; Krebs TL; Danielpour D
J Biol Chem; 2006 Mar; 281(12):7765-74. PubMed ID: 16428382
[TBL] [Abstract][Full Text] [Related]
11. Role of dihydrotestosterone (DHT) on TGF-β1 signaling pathway in epithelial ovarian cancer cells.
Kohan-Ivani K; Gabler F; Selman A; Vega M; Romero C
J Cancer Res Clin Oncol; 2016 Jan; 142(1):47-58. PubMed ID: 26091707
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor A, secreted in response to transforming growth factor-β1 under hypoxic conditions, induces autocrine effects on migration of prostate cancer cells.
Darrington E; Zhong M; Vo BH; Khan SA
Asian J Androl; 2012 Sep; 14(5):745-51. PubMed ID: 22705563
[TBL] [Abstract][Full Text] [Related]
13. Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.
Kalo E; Buganim Y; Shapira KE; Besserglick H; Goldfinger N; Weisz L; Stambolsky P; Henis YI; Rotter V
Mol Cell Biol; 2007 Dec; 27(23):8228-42. PubMed ID: 17875924
[TBL] [Abstract][Full Text] [Related]
14. Characterization of TGF-beta-regulated interleukin-8 expression in human prostate cancer cells.
Lu S; Dong Z
Prostate; 2006 Jun; 66(9):996-1004. PubMed ID: 16541418
[TBL] [Abstract][Full Text] [Related]
15. Syntenin regulates TGF-β1-induced Smad activation and the epithelial-to-mesenchymal transition by inhibiting caveolin-mediated TGF-β type I receptor internalization.
Hwangbo C; Tae N; Lee S; Kim O; Park OK; Kim J; Kwon SH; Lee JH
Oncogene; 2016 Jan; 35(3):389-401. PubMed ID: 25893292
[TBL] [Abstract][Full Text] [Related]
16. Aberrant TGF-β1 signaling contributes to the development of primary biliary cirrhosis in murine model.
Liu B; Zhang X; Zhang FC; Zong JB; Zhang W; Zhao Y
World J Gastroenterol; 2013 Sep; 19(35):5828-36. PubMed ID: 24124327
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor beta 1 and its receptor types I and II. Comparison in human normal prostate, benign prostatic hyperplasia, and prostatic carcinoma.
Royuela M; De Miguel MP; Bethencourt FR; Sanchez-Chapado M; Fraile B; Paniagua R
Growth Factors; 1998; 16(2):101-10. PubMed ID: 9932228
[TBL] [Abstract][Full Text] [Related]
18. Protein phosphatase 2A is a negative regulator of transforming growth factor-beta1-induced TAK1 activation in mesangial cells.
Kim SI; Kwak JH; Wang L; Choi ME
J Biol Chem; 2008 Apr; 283(16):10753-63. PubMed ID: 18299321
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of transforming growth factor (TGF) beta1 type II receptor restores TGF-beta1 sensitivity and signaling in human prostate cancer cells.
Guo Y; Kyprianou N
Cell Growth Differ; 1998 Feb; 9(2):185-93. PubMed ID: 9486855
[TBL] [Abstract][Full Text] [Related]
20. The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors.
Ungefroren H; Sebens S; Groth S; Gieseler F; Fändrich F
Curr Cancer Drug Targets; 2011 May; 11(4):524-35. PubMed ID: 21395548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
